Nrf2-IN-4

Nrf2-IN-4 (Compound PhcY) (0.01-10 μM, 72 h) exhibits inhibitory effect on the cancer cell lines, with IC₅₀s of 80 nM (MCF-7 cells), 3.26 μM (HepG2 cells), 0.90 μM (T24 cells), 2.89 μM (HCT116 cells), 3.27 μM (L929 fibroblasts) and 5.36 μM (HEK293 human embryonic kidney cells)^[1].
Nrf2-IN-4 (40-160 nM) causes MCF-7 cells to exhibit ‘ballooning’ and rounded cell morphology with vacuolated cytosol^[1].
Nrf2-IN-4 (40-80 nM, 14 days) inhibits colony formation of MCF-7 cells in a dose-dependent manner^[1].
Nrf2-IN-4 (80-160 nM, 24-48 h) increases labile iron pool (LIP) and ferroptosis via inhibition of Nrf2 in MCF-7 cells^[1].
Nrf2-IN-4 (80-320 nM, 24 h) induces lysosome activation by promoting iron-dependent ROS production and lysosomal acidification in MCF-7 cells^[1].
Nrf2-IN-4 (40-320 nM, 0-12 h) induces ferritin degradation via ferritinophagy in MCF-7 cells^[1].
Nrf2-IN-4 (80-320 nM) induces oxidative stress, resulting in a significant decrease in mitochondrial membrane potential, an effect that can be reduced by the Acetylcysteine (N-acetylcysteine) (NAC) (HY-B0215) in MCF-7 cells^[1].
Nrf2-IN-4 (0.1-0.2 μM) demonstrates a potent inhibitory effect on organoid growth, surpassing the efficacy of ML385(HY-100523)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.